Anti-obesity Pharmacotherapy and Inflammation

Active, not recruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

January 30, 2026

Study Completion Date

February 20, 2026

Conditions
Obesity
Interventions
DRUG

Semaglutide

Medication for weight loss

DRUG

Phentermine-Topiramate combination

Medication for weight loss

DRUG

Phentermine

Medication for weight loss

DRUG

Tirzepatide

Medication for weight loss

DRUG

Topiramate

Medication for weight loss

DRUG

Diethylpropion

Medication for weight loss

DRUG

Naltrexone/Bupropion

Medication for weight loss

DRUG

Liraglutide

Medication for weight loss

Trial Locations (2)

70112

LSU Clinical & Translational Research Center (CTRC - - LSUHSC-NO, New Orleans

70121

Ochsner Health System - Biospecimen, New Orleans

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Tulane University

OTHER

collaborator

Pennington Biomedical Research Center

OTHER

collaborator

Ochsner Health System

OTHER

lead

Louisiana State University Health Sciences Center in New Orleans

OTHER

NCT05756764 - Anti-obesity Pharmacotherapy and Inflammation | Biotech Hunter | Biotech Hunter